filings.toolsItem 2. PROPERTIES
3K characters. Original on sec.gov · Markdown
Item 2. PROPERTIES
Below is a summary of our significant properties owned and leased as of December 31, 2024.
| Location | Approximate Square Feet | Use | Owned/Leased | |||||||||||||||||
| U.S. | ||||||||||||||||||||
| Cambridge, Massachusetts | 263,000 | Research laboratory and cogeneration plant | Owned | |||||||||||||||||
| Cambridge, Massachusetts | 729,000 | Corporate headquarters and laboratory | Leased - Expires 2028 | |||||||||||||||||
| Weston, Massachusetts | 357,000 | Office | Leased - Expires 2025 | |||||||||||||||||
| RTP, North Carolina | 1,040,000 | Office, laboratory, manufacturing, warehouse | Owned | |||||||||||||||||
| Durham, North Carolina | 65,000 | Warehouse | Leased - Expires 2025 | |||||||||||||||||
| Plano, Texas | 327,000 | Office and laboratory | Leased - Expires 2038 | |||||||||||||||||
| International(1) | ||||||||||||||||||||
| Solothurn, Switzerland | 734,000 | Manufacturing facility, warehouse and office | Owned | |||||||||||||||||
| Baar, Switzerland | 81,800 | International headquarters | Leased - Expires 2028 |
(1) We also lease office space in other international regions including: the U.K.; Germany; France; Japan; Canada and numerous other countries. Our international lease agreements expire at various dates through the year 2034.
In the fourth quarter of 2021 we began construction of a new gene therapy, clinical packaging and other manufacturing facility in RTP, North Carolina to support our gene therapy pipeline across multiple therapeutic areas. The new manufacturing facility will be approximately 197,000 square feet. We estimate the construction of this manufacturing facility will be completed during 2025.
We believe that our our existing properties, including both owned and leased sites, are adequate and suitable for the conduct of our business. We believe our capital resources are sufficient to purchase, lease or construct any additional facilities required to meet our expected long-term growth needs.
Previous: Item 1C. CYBERSECURITY · Next: Item 3. LEGAL PROCEEDINGS